Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

doi:10.1158/1078-0432.CCR-12-0857

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2012

Wang Zhigang C, Birkbak Nicolai Juul, Culhane Aedín C, Drapkin Ronny, Fatima Aquila, Tian Ruiyang, Schwede Matthew, Alsop Kathryn, Daniels Kathryn E, Piao Huiying, Liu Joyce, Etemadmoghadam Dariush, Miron Alexander, Salvesen Helga B, Mitchell Gillian, DeFazio Anna, Quackenbush John, Berkowitz Ross S, Iglehart J Dirk, Bowtell David D L, Matulonis Ursula A

Abstract excerpt

PURPOSE: High-grade serous cancer (HGSC) is the most common cancer of the ovary and is characterized by chromosomal instability. Defects in homologous recombination repair (HRR) are associated with genomic instability in HGSC, and are exploited by therapy targeting DNA repair. Defective HRR causes uniparental deletions and loss of heterozygosity (LOH). Our purpose is to profile LOH in HGSC and correlate our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Genomic Instability

Share to Loss of Heterozygosity

Share to Neoplasm Grading

Share to Neoplasms, Cystic, Mucinous, and Serous

Share to Ovarian Neoplasms

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 22912389
DOI: 10.1158/1078-0432.CCR-12-0857
PMCID: PMC4205235

Genes

BRCA1
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.PMID 22912389Read ↗

Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian CancerSemantic proximity Read ↗

High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.Semantic proximity Read ↗

Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Genomic analyses of germline and somatic variation in high-grade serous ovarian cancerSemantic proximity Read ↗

Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.Semantic proximity Read ↗

Optimized detection of allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in cancerSemantic proximity Read ↗

Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.Semantic proximity Read ↗

Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancerSemantic proximity Read ↗

The Changing View of High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.Semantic proximity Read ↗

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.Semantic proximity Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.